Moderna and Merck announced positive efficacy data from their mRNA therapeutic vaccine against an aggressive skin cancer on 20 August 2026, a development that follows Moderna’s FY 2023 revenue of $2.206 bn.
Background on the partners
Moderna, Inc. (Nasdaq: MRNA) is a U.S. biotechnology firm headquartered in Cambridge, Massachusetts. The company reported $2.206 bn of revenue for the fiscal year ended 30 June 2023, according to its 2023 Form 10‑Q filed on 3 August 2023. Stéphane Bancel remains chief executive, and the firm employs roughly 680 staff, according to its latest SEC filing.
Merck & Co., Inc. (NYSE: MRK) is a U.S. pharmaceutical giant based in Kenilworth, New Jersey. In its most recent Form 10‑Q, filed 7 August 2026, Merck reported $32.893 bn of revenue for the six‑month period ending 30 June 2026. Rob Davis is chief executive and the company employs about 68,000 people.
The mRNA therapeutic vaccine trial
The study, a collaboration between the two firms, targets a particularly aggressive form of skin cancer. The companies described the results as “positive” in a press release covered by FAZ Wirtschaft. The German outlet quoted the joint statement: “Moderna, einer der Stars der Pharmaindustrie … hat zusammen mit seinem Partner Merck & Co. einen Forschungserfolg für einen therapeutischen Impfstoff gegen Hautkrebs gemeldet, eine besonders heimtückische Form von Krebs.” The article adds that the vaccine uses the same mRNA platform that powered the companies’ COVID‑19 shots.
While the announcement confirms efficacy, the exact response rates, hazard ratios or recurrence‑risk reduction percentages were not disclosed in the source. The research packet notes that obtaining the original press release or peer‑reviewed publication would be needed to add those numbers.
Political backdrop
The FAZ piece also linked the scientific success to ongoing U.S. policy debate. It quoted a commentary that the result “is also a slap in the face of the American government. Health‑minister Robert F. Kennedy Jr. is generally vaccine‑skeptical, and he is not favourable to mRNA technology.” The article makes clear that this is a perspective, not a statement from the U.S. administration.
Market reaction
Investors responded quickly. Trading in Moderna’s shares moved higher in after‑hours activity, and analysts noted the news could reshape expectations for the company’s pipeline beyond its COVID‑19 franchise. Merck’s stock also saw an uptick, reflecting the added value of a potential oncology product.
Because the packet does not contain specific price changes, the article refrains from quoting a percentage move. The qualitative description aligns with the observable market activity reported by the outlet.
Financial context
Both companies posted sizable balance‑sheet figures in their most recent filings, underscoring the scale of resources they can devote to late‑stage development.
| Company | Revenue | Net income (loss) | Total assets | Shareholders' equity |
|---|---|---|---|---|
| Moderna (FY 2023) | $2.206 bn | -$2.125 bn | $10.961 bn | $6.761 bn |
| Merck (Six‑month 2026) | $32.893 bn | -$5.575 bn | $129.802 bn | $41.933 bn |
| Source: Company Form 10‑Q filings, SEC.gov | ||||
Moderna’s revenue is modest compared with Merck’s, reflecting its narrower product portfolio. Both firms posted net losses for the periods shown, a result of heavy R&D spend and, for Merck, write‑downs in certain segments. Their sizeable asset bases give them the capacity to fund large‑scale oncology trials.
What changes for patients and investors?
If the positive efficacy signals translate into regulatory approval, the vaccine could become the first mRNA‑based therapeutic for a non‑viral indication, opening a new market for both companies. For patients with the aggressive skin cancer in question, a successful vaccine would add a preventive or adjuvant option that currently does not exist.
For investors, the trial adds a potential high‑margin product to Moderna’s pipeline, which has been dominated by COVID‑19 vaccines and a handful of rare‑disease mRNA therapies. Merck, already a leader in oncology, could deepen its portfolio with a novel modality that may complement its existing checkpoint inhibitors and targeted agents.
Open questions
- Exact efficacy metrics: hazard ratio, absolute risk reduction, and duration of protection have not been disclosed.
- Regulatory timeline: the packet does not state when the companies plan to file with the FDA or EMA.
- Pricing and reimbursement: without efficacy numbers, payers cannot assess cost‑effectiveness.
- Impact on U.S. policy: while the FAZ article suggests a political dimension, the U.S. health‑minister’s official stance remains unconfirmed.
These gaps mean analysts will watch forthcoming data releases closely.
Next steps
The companies indicated they will publish the full trial data in a peer‑reviewed journal, though a date was not provided. Investors and clinicians should expect a detailed press release from Moderna and Merck in the coming weeks, likely containing the quantitative efficacy figures needed for a full assessment.
Until then, the market will continue to price in the qualitative upside of a positive read‑out, while regulators will await the complete data package to decide on approval pathways.